(December 4, 2017) The results of a phase II trial, which focused on stages IIB to IVA epithelial ovarian cancer, were recently published in the Annals of Oncology. The primary … Continued
(November 22, 2017) A recent paper published in the Journal of Clinical Investigation reports that a subset of ovarian cancers reduce the expression of a critical gene involved in recycling … Continued
(October 30, 2017) Until recently, it was thought that high-grade serous ovarian carcinomas (HGSOCs) arose from the ovarian surface epithelium, but recent data from two studies published in Nature Communications … Continued
(October 20, 2017) An international, large scale study may have found a link between high-grade ovarian cancer and a type of white blood cell known as a tumor-infiltrating lymphocyte. Recently … Continued
(October 19, 2017) BRCA1 and BRCA2 are among the most frequently mutated genes in ovarian cancer. Studies conducted in the past two decades have shown that BRCA1 and BRCA2 play … Continued
(October 13, 2017) The National Comprehensive Cancer Network currently recommends that early stage Ovarian Clear Cell Cancers be treated with adjuvant chemotherapy, or therapy given after the primary treatment as … Continued
(October 13, 2017) Every other year, the American Association for Cancer Research (AACR) brings together ovarian cancer researchers from around the world to share knowledge and encourage multi-disciplinary collaboration. At … Continued
(September 15, 2017) Two studies just confirmed that, depending on one’s genetic background, the standard treatment for epithelial ovarian cancer is most likely the best option. The studies, conducted with … Continued
(September 5, 2017) Researchers at the University of Pennsylvania recently uncovered a link between one’s resistance to common types of chemotherapy and one’s tumor BRCA1/2 mutation status. More specifically, they … Continued
(August 22, 2017) The Journal of Clinical Oncology recently published a study about the unmet need of genetic testing in women with breast and ovarian cancer. Women who fit eligibility … Continued
(August 21, 2017) The US Food and Drug Administration (FDA) has granted full approval to olaparib tablets (Lynparza, AstraZeneca) for use as maintenance therapy for women with recurrent epithelial ovarian, … Continued
(August 9, 2017) The International Journal of Cancer recently published an article on preliminary findings for two factors that influence one’s risk of ovarian cancer, namely the age at which … Continued
Get email updates about research news, action alerts, and ways to join the fight.
